Last reviewed 2026-05-14 · How we verify

GSK 573719 62.5

GSK573719 is a long-acting muscarinic antagonist (LAMA) that blocks M3 receptors in airway smooth muscle to promote bronchodilation.

GSK573719 is a long-acting muscarinic antagonist (LAMA) that blocks M3 receptors in airway smooth muscle to promote bronchodilation. Used for Chronic obstructive pulmonary disease (COPD) maintenance therapy.

At a glance

Mechanism of action

By antagonizing muscarinic M3 receptors on airway smooth muscle, GSK573719 prevents acetylcholine-induced bronchoconstriction and promotes sustained airway relaxation. This mechanism is characteristic of anticholinergic bronchodilators used in chronic obstructive pulmonary disease (COPD) management. The long-acting formulation provides once-daily or twice-daily dosing for maintenance therapy.

Approved indications

• Chronic obstructive pulmonary disease (COPD) maintenance therapy

Common side effects

• Dry mouth
• Tremor
• Headache
• Nasopharyngitis

Key clinical trials

• An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A (PHASE3)
• A 3-period Crossover Study With GSK573719 as Monotherapy in Adult Subjects With Asthma (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• GSK 573719 62.5 CI brief — competitive landscape report
• GSK 573719 62.5 updates RSS · CI watch RSS
• GlaxoSmithKline portfolio CI